NCT04607200: AGEN2034 & AGEN1884 in Patients With Recurrent, Inoperable Angiosarcoma |
|
|
| Withdrawn | 2 | 0 | NA | AGEN2034, Anti-PD-1, AGEN1884, Anti-CTLA-4 | Agenus Inc. | Angiosarcoma | 09/21 | 09/21 | | |
NCT05864534: Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed Glioblastoma |
|
|
| Recruiting | 2 | 25 | US | Balstilimab, BAL, Botensilimab, BOT, Liposomal Doxorubicin, DOX, Sonocloud-9 (SC-9), SC-9 | Northwestern University, Agenus Inc., CarThera | Newly Diagnosed Glioblastoma, Glioblastoma, Isocitric Dehydrogenase (IDH)-Wildtype, Gliosarcoma, Glioblastoma Multiforme | 05/26 | 08/26 | | |
NCT04028063: Doxorubicin Plus Dual Checkpoint Blockade for Soft Tissue Sarcomas |
|
|
| Recruiting | 2 | 28 | US | doxorubicin with AGEN1884 and AGEN2034 | University of Colorado, Denver, Agenus Inc. | Metastatic Soft Tissue Sarcoma, Advanced Soft Tissue Sarcoma | 11/24 | 11/25 | | |
